Introduction
Introduction
The development of linear echo-endoscopes has opened up fascinating new diagnostic
possibilities for patients with various lung diseases. Transoesophageal ultrasound-guided
fine needle aspiration (EUS-FNA) and transbronchial ultrasound-guided needle aspiration
(EBUS-TBNA) are both minimally invasive diagnostic techniques that enable real-time
controlled aspirations of mediastinal lymph nodes and centrally located lung tumours.
By demonstrating mediastinal metastases, surgical procedures can frequently be avoided.
In this short survey, we provide an overview concerning results obtained by EUS and
EBUS in pulmonary medicine and discuss how these novel methods can be used in clinical
practise.
EUS- FNA
EUS- FNA
Linear echo-endoscopes (Fig. [1]) were originally developed for diagnostic purposes in gastero-enterology. By incorporating
an ultrasound transducer at the tipp of an endoscope, para-oesophageal lesions can
be aspirated under real-time ultrasound guidance. In 1996, it was suggested that EUS
was also a useful diagnostic method for mediastinal lesions of unknown origin [1]. Initial EUS studies for mediastinal abnormalities were often performed by gastro-enterologists
who frequently first performed a radial EUS - which provides a 360 degree overview
of the para-oesophageal area. Once suspected lesions were identified, they were aspirated
those using linear equipment. As ultrasound criteria of lymph nodes alone - such as
shape, size, demarcation and echo pattern - are not accurate enough to distinguish
between malignant and benign nodes, fine needle aspirations are needed for an accurate
assessment [2]
[3]
[4]. Nodes as small as 4 mm can be aspirated [5], and on site cytology is advocated in order to assess whether representative material
has been obtained [6]. For its use in pulmonary medicine, we believe that linear equipment should be used
primarily, as in the overwhelming majority of cases tissue verification is needed.
An EUS investigation is performed under ambulatory conditions, often under conscious
sedation, and takes on average 20 - 25 minutes. EUS-FNA should be performed in a standardized
fashion in order to visualize the left adrenal gland, left liver lobe and all mediastinal
nodes that that can be assessed from the oesophagus. EUS in particular provides access
to nodes in the lower mediastinum (station 7,8,9) (Fig. [2]). Nodes located in the aorta-pulmonary window (station 5) and adjacent to the aorta
(station 6) can easily be identified but not all these nodes can be safely targeted
due to intervening vascular structures. Lymph nodes located pre- and para-tracheally
(station 2 and 4) often cannot be detected by EUS due to intervening air, especially
in those located on the right side of the trachea. The diagnostic reach of EUS is
complementary with that of mediastinoscopy and EBUS [7] (Fig. [2]).
Fig. 1 Linear oesophageal (Pentax FG 34 UX) and bronchial (bottom) endo-echo scopes (Olympus
BF UC 160F).
Fig. 2 Staging methods and their range in assessing regional lymph node stations [48] in non-small cell lung cancer [49].
EBUS-TBNA
EBUS-TBNA
Transbronchial needle aspiration (TBNA) of mediastinal lesions has been reported since
the 1940’s and can be performed during routine bronchoscopy. The sensitivity varies
enormously (17 - 84 %) and is dependent on the prevalence of mediastinal metastases
in the population under investigation and experience of the investigators [8]. Currently, ”blind” TBNA is only performed by 27 % of chest physicians [9] - the main reason for its limited use being the lack of real time monitoring of
the needle [10]. The yield of TBNA can be increased, especially for those nodes located outside
the subcarinal region [11], by using endobronchial ultrasound (EBUS) to locate the node prior to TBNA [12]. To achieve images with radial EBUS, an ultrasound probe and a water filled balloon
are needed. A limitation of this radial EBUS ”localisation method” is that the aspiration
itself is still being performed in a blind fashion. Very recently, linear EBUS probes
with a side viewing optic and a curved linear array ultrasound transducer have been
developed by which hilar and mediastinal lymph nodes can be aspirated under real-time
ultrasound control from the trachea bronchial tree [13]. With EBUS-TBNA the para-tracheal (stations 2 and 4), subcarinal (station 7) hilar
and intrapulmonary nodes (stations 10 and 11) can be reached. EBUS investigations
occur both under local and general anaesthesia and take around 20 minutes. In the
near future, further technological improvements are expected, especially regarding
the quality of the ultrasound signal. Due to their size and side viewing optic a complete
inspection of the bronchial system is not possible. The diagnostic range of EBUS overlaps
with that of mediastinoscopy and is complementary with EUS (Fig. [2]) [7], [13]
[14]
[15].
Diagnosis and staging of lung cancer
Diagnosis and staging of lung cancer
Undoubtedly, mediastinal lymph node staging in patients with (suspected) lung cancer
is the main indication for EUS and EBUS. Additionally, EUS and EBUS might be helpful
in the assessment of mediastinal tumour invasion (T4) or - in the case of EUS-left
adrenal metastases (M1). For EUS-FNA, the vast majority of studies have been performed
in selected lung cancer patients with enlarged mediastinal nodes on computed tomogram
(CT) of the chest for which it has accuracy above 90 % [14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]. Two studies addressed the value of EUS in small nodes for which an accuracy of
73 % and 82 % has been reported [22]
[23]. For mediastinal restaging after neo adjuvant chemotherapy an accuracy of 83 % has
been assessed [24]. EUS in combination with mediastinoscopy improves loco regional staging [17]
[25] and thus prevents futile thoracotomies [26]. Regarding EBUS-TBNA, two medium sized studies reported an accuracy of more than
96 % in distinguishing benign from malignant mediastinal nodes in patients with (suspected)
lung cancer [13]
[27]. Analysis of lesions that are suspect for malignancy based of FDG-PET by either
EUS-FNA [18]
[28]
[29] or TBNA after EBUS localisation [30] has been advocated as a minimally invasive staging strategy for patients with NSCLC.
In up to 30 % of patients with suspected lung cancer, no tissue diagnosis is obtained
by bronchoscopy. In those patients with enlarged mediastinal nodes, tissue proof of
mediastinal malignancy - either by EUS or EBUS - provides both a diagnosis and loco-regional
staging in a single test [16]
[27]. In those patients with suspected lung cancer and the primary tumour located adjacent
to the oesophagus, intrapulmonary tumours can be visualised and aspirated by EUS [31]
[32]. In one study in 32 patients, EUS established a tissue diagnosis in 97 % of patients
after a prior non-diagnostic bronchoscopy [31]. It has been reported that EUS can assess mediastinal tumour invasion provided the
tumour is detected by EUS [17]
[33]
[34]. In 97 patients with left sided tumours located adjacent to the aorta EUS (Fig.
[3]) had an accuracy for mediastinal tumour invasion of 92 % [34]. Cells from the left adrenal gland can be aspirated by EUS-FNA from the stomach.
In a study of 31 patients with suspected malignancy and enlarged left adrenal glands,
EUS-FNA demonstrated metastases in 42 % of patients [35]. Whether the left adrenal gland should be investigated routinely during EUS - regardless
of its size at CT is subject of debate [36].
Fig. 3 Left upper lobe tumor (T) located adjacent to the aorta (AO) without sonographic signs
of tumor invasion (T4) (Es = esophagus).
Granulomatous diseases
Granulomatous diseases
Sarcoidosis and tuberculosis are common diseases in which a tissue diagnosis or culture
is often needed for diagnostic and treatment purposes. As the mediastinal nodes are
frequently involved in these diseases, EUS and EBUS might be helpful in the diagnostic
process. EUS-FNA has been demonstrated to have a yield of 82 % [37] and sensitivity of 89 - 94 % [38]
[39] by assessing non-caseating granulomas in mediastinal nodes in patients with suspected
sarcoidosis. Ultrasonic images frequently display a typical pattern of clustered iso-echoic
nodes (Fig. [4]) [37] with sometimes prominent vessels [38]. Studies regarding the diagnostic value of EBUS-TBNA in patients with suspected
sarcoidosis are ongoing. For the diagnosis of sarcoidosis, bronchoscopy with TBNA
and transbronchial lung biopsies have a yield in assessing granulomas of around 66
% [40]. We expect an important role or both EUS and probably EBUS in the diagnostic workup
for patients with sarcoidosis as EUS has a high yield in demonstrating granulomas
and no risk of haemoptysis and pneumothoraces, complications that are described for
transbronchial biopsies. Samples obtained by EUS can be sent for culture for Tuberculosis
[19] as well as PCR analysis.
Fig. 4 Multiple iso-echoic mediastinal and hilar lymph nodes (LN) located adjacent to the
esophagus (ES), aorta (AO), and pulmonary artery (PA) in a patient with sarcoidosis.
Miscellaneous
Miscellaneous
EUS can be useful for the diagnosis of other diseases besides lung cancer and granulomatous
disorders. Mediastinal cysts - compromising 20 % of mediastinal lesions - are often
difficult to diagnose. On EUS, cysts frequently have a specific round form with a
echo free interior, although the content of cysts can be very variable [41]. Although EUS could be helpful in the differential diagnosis of a mediastinal lesion,
it is not recommended to aspirate cysts due to the risk of infection and mediastinitis
[41]
[42]. Obviously, mediastinal metastases other than from pulmonary malignancies can be
assessed by either EUS or EBUS. EUS-FNA has been demonstrated to assess mediastinal
metastases from head and neck neoplasms [43], colon, renal, bladder carcinoma carcinomas and melanomas [44]. Although it has been reported that EUS with flow cytometry can be used for the
diagnosis of lymphomas [6]
[45]
[46], the diagnostic role of EUS for this indication is under debate as haematologists
often prefer large histological samples for the initial diagnostic assessment.
Impact on patient management
Impact on patient management
One of the big advancements of EUS and EBUS is related to the fact that these methods
enable minimally invasive tissue sampling of regions that are otherwise only accessible
by invasive surgical procedures such as mediastinoscopy/ tomy, or even open thoracotomy.
In operable patients with (suspected) lung cancer and enlarged mediastinal nodes,
EUS and prevented 70 % of scheduled mediastinoscopies [16]
[20]. As EUS and mediastinoscopy are complementary in their diagnostic reach [17]
[25]
[26] additional staging of EUS to mediastinoscopy improves staging [17]
[25] and reduces futile thoracotomies [26]. In patients with lung cancer without enlarged nodes, EUS findings changed patient
management in 25 % of cases [22]
[23]. By demonstrating left adrenal metastases, EUS prevented CT guided biopsies [22] which usually require a separate patient appointment. In a recent study in 105 patients
with (suspected) lung cancer and enlarged hilar or mediastinal nodes, EBUS-TBNA prevented
mediastinoscopies in 29, thoracotomies in 8, thoracoscopies in 4 and CT guided needle
biopsies in 9 patients (total 48 %) [27].
Future goals and perspectives
Future goals and perspectives
In 2006, there is a substantial body of evidence that EUS-FNA is an accurate method
for the diagnosis and staging of lung cancer with a large impact on patient management.
Therefore, in our opinion, it is not the question if but how and on which scale and
within which time frame EUS will be implemented in the daily practice in pulmonary
medicine. For several indications more data are needed, in particular regarding small
nodes, mediastinal restaging and the assessment of tumour invasion. As the EBUS-TBNA
scopes have been available for just a few years, as yet limited data are available.
The first results of EBUS in the diagnosis and staging lung cancer are promising [13]
[14]
[27]. EUS and EBUS are complementary in their diagnostic reach [7] and combined endoscopic staging by both methods (Fig. [1]) has been suggested [14]
[15]. For those lesions/ nodal stations that can be reached by either method, more comparison
studies [7] are needed. For such studies not only yield and diagnostic accuracy, but also feasibility
tolerability and patient preference should be taken into account. Lung cancer staging
algorithms are under debate [47] with the rapidly increasing clinical availability of EUS, EBUS and PET. Each of
these techniques as well as existing methods such as mediastinoscopy and VATS have
their specific limitations and to date it is not clear what the optimal staging algorithm
for lung cancer should be. Prospective staging studies between EUS, EBUS, PET mediastinoscopy
and VATS should investigate several staging strategies. For sarcoidosis, comparative
studies between conventional bronchoscopy with blind TBNA and TBLB, EBUS-TBNA and
EUS-FNA should be performed that do not only take diagnostic yield but also complications
and patient tolerability and preference into account.
Training and implementation of EUS will be important issues in the years to come.
The lack of training facilities for EUS provides a barrier for further implementation.
It remains to be seen whether the published results, mostly obtained by ”dedicated
enthusiasts” in expert centres, will be reproducible by less experienced investigators.
Most courses that are organised in expert centers provide participants with a good
overview of the indications for EUS (Table [1]), but in order to get acquainted with EUS, hands-on training over a longer period
seems to be the desirable. To perform mediastinal EUS in pulmonary medicine on a top
level, there is more to it than just aspirating a para-oesophageal node. Investigators
should be aware of indications and limitations of EUS as well as alternative approaches
to solve the diagnostic problem under investigation. Additionally, a thorough knowledge
of the various mediastinal nodal stations should be present.
In conclusion, both EUS-FNA and EBUS-TBNA are fascinating novel diagnostic methods
that enable tissue verification of mediastinal and intrapulmonary lesions in a minimally
invasive way and, therefore, prevent surgical interventions to a large extent. More
training facilities are urgently needed in order to ensure that all patients get access
to these novel diagnostic methods.
Table 1 Indications for EUS-FNA in Pulmonary Medicine
Suspected lung cancer, enlarged (> 1 cm) mediastinal lymph nodes#
|
Suspected lung cancer, primary tumour located adjacent to the esophagus |
Mediastinal staging of non-small cell lung cancer#
|
Mediastinal involvement at FDG-PET in (suspected) lung cancer#
|
Mediastinal restaging after induction chemotherapy |
Assessment of tumour invasion (T4) in centrally located tumours |
Suspected mediastinal metastasis from extra thoracic tumours |
Suspected Sarcoidosis |
Suspected Tuberculosis |
Suspected Cysts (no FNA) |
# Indications also for EBUS-TBNA |